nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—NR3C1—Medroxyprogesterone Acetate—uterine cancer	0.264	0.602	CbGbCtD
Fluocinonide—Flurandrenolide—Medroxyprogesterone Acetate—uterine cancer	0.18	0.414	CrCrCtD
Fluocinonide—NR3C1—Progesterone—uterine cancer	0.175	0.398	CbGbCtD
Fluocinonide—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	0.132	0.303	CrCrCtD
Fluocinonide—Methylprednisolone—Medroxyprogesterone Acetate—uterine cancer	0.123	0.283	CrCrCtD
Fluocinonide—SERPINA6—oviduct—uterine cancer	0.00858	0.166	CbGeAlD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—SPOP—uterine cancer	0.00555	0.194	CbGpPWpGaD
Fluocinonide—Cushing's syndrome—Medroxyprogesterone Acetate—uterine cancer	0.00502	0.114	CcSEcCtD
Fluocinonide—SMO—myometrium—uterine cancer	0.00498	0.0965	CbGeAlD
Fluocinonide—SMO—uterine cervix—uterine cancer	0.00388	0.0751	CbGeAlD
Fluocinonide—SMO—endometrium—uterine cancer	0.00351	0.0679	CbGeAlD
Fluocinonide—SMO—mammalian vulva—uterine cancer	0.00339	0.0657	CbGeAlD
Fluocinonide—SMO—uterus—uterine cancer	0.00323	0.0626	CbGeAlD
Fluocinonide—SMO—female reproductive system—uterine cancer	0.00291	0.0563	CbGeAlD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—INHBA—uterine cancer	0.00276	0.0964	CbGpPWpGaD
Fluocinonide—SMO—female gonad—uterine cancer	0.00264	0.0512	CbGeAlD
Fluocinonide—SMO—vagina—uterine cancer	0.00263	0.0509	CbGeAlD
Fluocinonide—SERPINA6—renal system—uterine cancer	0.002	0.0387	CbGeAlD
Fluocinonide—SMO—lymph node—uterine cancer	0.0017	0.0329	CbGeAlD
Fluocinonide—SERPINA6—female reproductive system—uterine cancer	0.0016	0.031	CbGeAlD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.00147	0.0514	CbGpPWpGaD
Fluocinonide—Eruption—Dactinomycin—uterine cancer	0.00144	0.0328	CcSEcCtD
Fluocinonide—Folliculitis—Dactinomycin—uterine cancer	0.00141	0.0321	CcSEcCtD
Fluocinonide—Glycosuria—Medroxyprogesterone Acetate—uterine cancer	0.00141	0.0319	CcSEcCtD
Fluocinonide—Secondary infection—Epirubicin—uterine cancer	0.00123	0.0279	CcSEcCtD
Fluocinonide—NR3C1—myometrium—uterine cancer	0.0012	0.0233	CbGeAlD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—FGFR2—uterine cancer	0.00116	0.0406	CbGpPWpGaD
Fluocinonide—Secondary infection—Doxorubicin—uterine cancer	0.00113	0.0258	CcSEcCtD
Fluocinonide—Swelling—Progesterone—uterine cancer	0.00103	0.0235	CcSEcCtD
Fluocinonide—Nasal congestion—Progesterone—uterine cancer	0.001	0.0228	CcSEcCtD
Fluocinonide—NR3C1—epithelium—uterine cancer	0.000943	0.0183	CbGeAlD
Fluocinonide—Swelling—Medroxyprogesterone Acetate—uterine cancer	0.000937	0.0213	CcSEcCtD
Fluocinonide—NR3C1—uterine cervix—uterine cancer	0.000935	0.0181	CbGeAlD
Fluocinonide—NR3C1—smooth muscle tissue—uterine cancer	0.000909	0.0176	CbGeAlD
Fluocinonide—NR3C1—decidua—uterine cancer	0.000891	0.0173	CbGeAlD
Fluocinonide—NR3C1—renal system—uterine cancer	0.000875	0.017	CbGeAlD
Fluocinonide—Infection—Carboplatin—uterine cancer	0.000848	0.0193	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—uterine cancer	0.000848	0.0193	CcSEcCtD
Fluocinonide—NR3C1—endometrium—uterine cancer	0.000846	0.0164	CbGeAlD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000822	0.0287	CbGpPWpGaD
Fluocinonide—NR3C1—mammalian vulva—uterine cancer	0.000818	0.0159	CbGeAlD
Fluocinonide—Nasopharyngitis—Progesterone—uterine cancer	0.000816	0.0185	CcSEcCtD
Fluocinonide—Leukoderma—Doxorubicin—uterine cancer	0.000784	0.0178	CcSEcCtD
Fluocinonide—NR3C1—uterus—uterine cancer	0.000779	0.0151	CbGeAlD
Fluocinonide—Dry skin—Medroxyprogesterone Acetate—uterine cancer	0.000758	0.0172	CcSEcCtD
Fluocinonide—Nasopharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.000739	0.0168	CcSEcCtD
Fluocinonide—Pain—Carboplatin—uterine cancer	0.00073	0.0166	CcSEcCtD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—PIK3CA—uterine cancer	0.000712	0.0249	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Progesterone—uterine cancer	0.000711	0.0162	CcSEcCtD
Fluocinonide—NR3C1—female reproductive system—uterine cancer	0.000701	0.0136	CbGeAlD
Fluocinonide—Hyperglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.000645	0.0146	CcSEcCtD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—CTNNB1—uterine cancer	0.000639	0.0223	CbGpPWpGaD
Fluocinonide—NR3C1—female gonad—uterine cancer	0.000638	0.0124	CbGeAlD
Fluocinonide—NR3C1—vagina—uterine cancer	0.000634	0.0123	CbGeAlD
Fluocinonide—Skin exfoliation—Etoposide—uterine cancer	0.000614	0.0139	CcSEcCtD
Fluocinonide—Eruption—Epirubicin—uterine cancer	0.000586	0.0133	CcSEcCtD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—AKT1—uterine cancer	0.000581	0.0203	CbGpPWpGaD
Fluocinonide—Folliculitis—Epirubicin—uterine cancer	0.000573	0.013	CcSEcCtD
Fluocinonide—Immune system disorder—Progesterone—uterine cancer	0.00057	0.013	CcSEcCtD
Fluocinonide—Erythema—Progesterone—uterine cancer	0.000549	0.0125	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—uterine cancer	0.000542	0.0123	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—uterine cancer	0.000531	0.0121	CcSEcCtD
Fluocinonide—Swelling—Etoposide—uterine cancer	0.000529	0.012	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000527	0.0184	CbGpPWpGaD
Fluocinonide—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000517	0.0117	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptors—PGR—uterine cancer	0.00051	0.0178	CbGpPWpGaD
Fluocinonide—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.000498	0.0113	CcSEcCtD
Fluocinonide—Fluticasone Propionate—PGR—uterine cancer	0.000495	0.241	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000489	0.0171	CbGpPWpGaD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—YWHAE—uterine cancer	0.000487	0.017	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—HNF1B—uterine cancer	0.000474	0.0166	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000465	0.0106	CcSEcCtD
Fluocinonide—Betamethasone—PGR—uterine cancer	0.000453	0.221	CrCbGaD
Fluocinonide—NR3C1—Nuclear Receptors—ESR2—uterine cancer	0.000449	0.0157	CbGpPWpGaD
Fluocinonide—Infection—Progesterone—uterine cancer	0.000445	0.0101	CcSEcCtD
Fluocinonide—Glycosuria—Epirubicin—uterine cancer	0.000445	0.0101	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000444	0.0155	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Progesterone—uterine cancer	0.00044	0.00999	CcSEcCtD
Fluocinonide—Skin disorder—Progesterone—uterine cancer	0.000436	0.0099	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000421	0.00956	CcSEcCtD
Fluocinonide—Glycosuria—Doxorubicin—uterine cancer	0.000412	0.00935	CcSEcCtD
Fluocinonide—NR3C1—lymph node—uterine cancer	0.00041	0.00794	CbGeAlD
Fluocinonide—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000404	0.00917	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.000403	0.0141	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000398	0.00905	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000398	0.0139	CbGpPWpGaD
Fluocinonide—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000395	0.00897	CcSEcCtD
Fluocinonide—Erythema—Dactinomycin—uterine cancer	0.000388	0.00882	CcSEcCtD
Fluocinonide—Pain—Progesterone—uterine cancer	0.000383	0.00871	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—uterine cancer	0.000356	0.00809	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.000355	0.0124	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP11A1—uterine cancer	0.00035	0.17	CrCbGaD
Fluocinonide—Skin exfoliation—Epirubicin—uterine cancer	0.000344	0.00782	CcSEcCtD
Fluocinonide—Hypersensitivity—Progesterone—uterine cancer	0.00033	0.00751	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—uterine cancer	0.00033	0.00749	CcSEcCtD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—AKT1—uterine cancer	0.000323	0.0113	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Doxorubicin—uterine cancer	0.000318	0.00723	CcSEcCtD
Fluocinonide—Pruritus—Progesterone—uterine cancer	0.000317	0.00721	CcSEcCtD
Fluocinonide—Infection—Dactinomycin—uterine cancer	0.000315	0.00715	CcSEcCtD
Fluocinonide—Betamethasone—CYP19A1—uterine cancer	0.000311	0.151	CrCbGaD
Fluocinonide—NR3C1—Endoderm Differentiation—EZH2—uterine cancer	0.000304	0.0106	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000299	0.0068	CcSEcCtD
Fluocinonide—Dizziness—Progesterone—uterine cancer	0.000297	0.00674	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000296	0.0104	CbGpPWpGaD
Fluocinonide—Immune system disorder—Etoposide—uterine cancer	0.000292	0.00663	CcSEcCtD
Fluocinonide—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000287	0.00653	CcSEcCtD
Fluocinonide—Rash—Progesterone—uterine cancer	0.000283	0.00642	CcSEcCtD
Fluocinonide—Dermatitis—Progesterone—uterine cancer	0.000282	0.00642	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IRF1—uterine cancer	0.000282	0.00983	CbGpPWpGaD
Fluocinonide—Headache—Progesterone—uterine cancer	0.000281	0.00638	CcSEcCtD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—uterine cancer	0.000272	0.00952	CbGpPWpGaD
Fluocinonide—NR3C1—Nuclear Receptors—ESR1—uterine cancer	0.000272	0.00952	CbGpPWpGaD
Fluocinonide—Pain—Dactinomycin—uterine cancer	0.000271	0.00616	CcSEcCtD
Fluocinonide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000269	0.0061	CcSEcCtD
Fluocinonide—Dexamethasone—PGR—uterine cancer	0.000264	0.128	CrCbGaD
Fluocinonide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000256	0.00582	CcSEcCtD
Fluocinonide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000256	0.00582	CcSEcCtD
Fluocinonide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000255	0.00578	CcSEcCtD
Fluocinonide—Dry skin—Epirubicin—uterine cancer	0.00024	0.00545	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000238	0.0054	CcSEcCtD
Fluocinonide—Nasopharyngitis—Epirubicin—uterine cancer	0.000234	0.00531	CcSEcCtD
Fluocinonide—Hypersensitivity—Dactinomycin—uterine cancer	0.000234	0.00531	CcSEcCtD
Fluocinonide—Infection—Etoposide—uterine cancer	0.000228	0.00518	CcSEcCtD
Fluocinonide—Skin disorder—Etoposide—uterine cancer	0.000223	0.00506	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—uterine cancer	0.000222	0.00504	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000218	0.0076	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Doxorubicin—uterine cancer	0.000216	0.00492	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.000215	0.00752	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—SMAD3—uterine cancer	0.00021	0.00732	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Epirubicin—uterine cancer	0.000204	0.00463	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000201	0.00704	CbGpPWpGaD
Fluocinonide—Rash—Dactinomycin—uterine cancer	0.0002	0.00454	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—uterine cancer	0.0002	0.00697	CbGpPWpGaD
Fluocinonide—Pain—Etoposide—uterine cancer	0.000196	0.00446	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—HMGA1—uterine cancer	0.000191	0.00666	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.00019	0.00665	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Doxorubicin—uterine cancer	0.000189	0.00429	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000185	0.00648	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD3—uterine cancer	0.000182	0.00637	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP19A1—uterine cancer	0.000181	0.0881	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000177	0.00618	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Etoposide—uterine cancer	0.000169	0.00384	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—AKR1B10—uterine cancer	0.000169	0.00589	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000168	0.00585	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—ESR1—uterine cancer	0.000167	0.00584	CbGpPWpGaD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—uterine cancer	0.000166	0.0058	CbGpPWpGaD
Fluocinonide—Immune system disorder—Epirubicin—uterine cancer	0.000163	0.00371	CcSEcCtD
Fluocinonide—Pruritus—Etoposide—uterine cancer	0.000162	0.00369	CcSEcCtD
Fluocinonide—Erythema—Epirubicin—uterine cancer	0.000158	0.00358	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000157	0.00549	CbGpPWpGaD
Fluocinonide—Dizziness—Etoposide—uterine cancer	0.000152	0.00345	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—uterine cancer	0.000151	0.00344	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—uterine cancer	0.000149	0.00519	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CCL2—uterine cancer	0.000147	0.00514	CbGpPWpGaD
Fluocinonide—Erythema—Doxorubicin—uterine cancer	0.000146	0.00331	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000145	0.00507	CbGpPWpGaD
Fluocinonide—Rash—Etoposide—uterine cancer	0.000145	0.00329	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—uterine cancer	0.000145	0.00328	CcSEcCtD
Fluocinonide—Headache—Etoposide—uterine cancer	0.000144	0.00326	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—SOCS3—uterine cancer	0.000143	0.00499	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000142	0.00497	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—RNF43—uterine cancer	0.00014	0.00488	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CCL2—uterine cancer	0.000134	0.00467	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000133	0.00303	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000131	0.00457	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN2A—uterine cancer	0.000128	0.00448	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—INHBA—uterine cancer	0.000128	0.00446	CbGpPWpGaD
Fluocinonide—Infection—Epirubicin—uterine cancer	0.000128	0.0029	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000127	0.00442	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Epirubicin—uterine cancer	0.000126	0.00286	CcSEcCtD
Fluocinonide—Skin disorder—Epirubicin—uterine cancer	0.000125	0.00284	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—SMAD3—uterine cancer	0.000125	0.00436	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—EP300—uterine cancer	0.000125	0.00435	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000123	0.0028	CcSEcCtD
Fluocinonide—NR3C1—Circadian Clock—EP300—uterine cancer	0.000121	0.00423	CbGpPWpGaD
Fluocinonide—Infection—Doxorubicin—uterine cancer	0.000118	0.00269	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—uterine cancer	0.000117	0.00265	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—CXCL8—uterine cancer	0.000116	0.00406	CbGpPWpGaD
Fluocinonide—Skin disorder—Doxorubicin—uterine cancer	0.000116	0.00263	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—AKR1C1—uterine cancer	0.000115	0.00402	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN1B—uterine cancer	0.000114	0.00397	CbGpPWpGaD
Fluocinonide—Pain—Epirubicin—uterine cancer	0.00011	0.0025	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—CTNNB1—uterine cancer	0.00011	0.00384	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CTNNB1—uterine cancer	0.000107	0.00375	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000107	0.00373	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CXCL8—uterine cancer	0.000106	0.0037	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—PTEN—uterine cancer	0.000105	0.00365	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—uterine cancer	0.000103	0.00358	CbGpPWpGaD
Fluocinonide—Pain—Doxorubicin—uterine cancer	0.000102	0.00231	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—EP300—uterine cancer	9.98e-05	0.00348	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Epirubicin—uterine cancer	9.47e-05	0.00215	CcSEcCtD
Fluocinonide—NR3C1—Gene Expression—PHF1—uterine cancer	9.45e-05	0.0033	CbGpPWpGaD
Fluocinonide—Pruritus—Epirubicin—uterine cancer	9.1e-05	0.00207	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	8.88e-05	0.0031	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKR1C3—uterine cancer	8.86e-05	0.00309	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—uterine cancer	8.79e-05	0.00307	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Doxorubicin—uterine cancer	8.77e-05	0.00199	CcSEcCtD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	8.74e-05	0.00305	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PGR—uterine cancer	8.63e-05	0.00301	CbGpPWpGaD
Fluocinonide—Dizziness—Epirubicin—uterine cancer	8.5e-05	0.00193	CcSEcCtD
Fluocinonide—Pruritus—Doxorubicin—uterine cancer	8.42e-05	0.00191	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—YWHAE—uterine cancer	8.23e-05	0.00288	CbGpPWpGaD
Fluocinonide—Rash—Epirubicin—uterine cancer	8.11e-05	0.00184	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—uterine cancer	8.1e-05	0.00184	CcSEcCtD
Fluocinonide—Headache—Epirubicin—uterine cancer	8.06e-05	0.00183	CcSEcCtD
Fluocinonide—NR3C1—Gene Expression—CHD4—uterine cancer	8.04e-05	0.00281	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FBXW7—uterine cancer	7.89e-05	0.00276	CbGpPWpGaD
Fluocinonide—Dizziness—Doxorubicin—uterine cancer	7.87e-05	0.00179	CcSEcCtD
Fluocinonide—Rash—Doxorubicin—uterine cancer	7.5e-05	0.0017	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—uterine cancer	7.49e-05	0.0017	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—uterine cancer	7.45e-05	0.00169	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—uterine cancer	7.14e-05	0.00249	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—PGR—uterine cancer	6.97e-05	0.00243	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—STK11—uterine cancer	6.9e-05	0.00241	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CCL2—uterine cancer	6.87e-05	0.0024	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—SUZ12—uterine cancer	6.73e-05	0.00235	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—CTNNB1—uterine cancer	6.54e-05	0.00228	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SOCS3—uterine cancer	6.46e-05	0.00226	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—uterine cancer	6.29e-05	0.0022	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN2B—uterine cancer	6.19e-05	0.00216	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR2—uterine cancer	6.13e-05	0.00214	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	6.13e-05	0.00214	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF1R—uterine cancer	6.01e-05	0.0021	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	5.65e-05	0.00197	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SMAD3—uterine cancer	5.65e-05	0.00197	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CXCL8—uterine cancer	5.43e-05	0.0019	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGFR2—uterine cancer	5.39e-05	0.00188	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	5.36e-05	0.00187	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—uterine cancer	5.31e-05	0.00186	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—EP300—uterine cancer	5.26e-05	0.00184	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—CDKN2B—uterine cancer	4.99e-05	0.00174	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	4.98e-05	0.00174	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ESR1—uterine cancer	4.61e-05	0.00161	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—SMAD3—uterine cancer	4.56e-05	0.00159	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—NRAS—uterine cancer	4.36e-05	0.00152	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCL2—uterine cancer	4.06e-05	0.00142	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—KRAS—uterine cancer	3.75e-05	0.00131	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR1—uterine cancer	3.72e-05	0.0013	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CA—uterine cancer	3.44e-05	0.0012	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB2—uterine cancer	3.38e-05	0.00118	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PGR—uterine cancer	3.35e-05	0.00117	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCL8—uterine cancer	3.21e-05	0.00112	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—HRAS—uterine cancer	3.19e-05	0.00111	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EZH2—uterine cancer	3.19e-05	0.00111	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN1B—uterine cancer	3.13e-05	0.00109	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CTNNB1—uterine cancer	2.96e-05	0.00103	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR2—uterine cancer	2.95e-05	0.00103	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTEN—uterine cancer	2.88e-05	0.00101	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—AKT1—uterine cancer	2.81e-05	0.000983	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EP300—uterine cancer	2.75e-05	0.000961	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VEGFA—uterine cancer	2.61e-05	0.00091	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NRAS—uterine cancer	2.57e-05	0.000899	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—CDKN2B—uterine cancer	2.4e-05	0.000839	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KRAS—uterine cancer	2.21e-05	0.000774	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—SMAD3—uterine cancer	2.19e-05	0.000766	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CA—uterine cancer	2.03e-05	0.000711	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—uterine cancer	1.97e-05	0.000688	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HRAS—uterine cancer	1.88e-05	0.000658	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR1—uterine cancer	1.79e-05	0.000625	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKT1—uterine cancer	1.66e-05	0.000581	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—AKT1—uterine cancer	6.46e-06	0.000226	CbGpPWpGaD
